The multidisciplinary Norton Children’s Cancer Predisposition Program is designed to identify, monitor and support children who have inherited genetic conditions that increase their lifetime risk of cancer. The program established in November 2024 is a collaborative effort between Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine, and Norton Children’s Genetics Center, also…
Cancer care offered through Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine, is ranked among the top 50 pediatric cancer programs nationwide by U.S. News & World Report in its 2024–2025 Best Children’s Hospitals rankings. This recognition reflects the commitment to excellence at Norton Children’s Cancer Institute, evident in a comprehensive array…
Mustafa Barbour, M.D., pediatric neuro-oncologist with Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine, is working to advance pediatric neuro-oncology care in Kentucky, where the incidence of pediatric brain tumors exceeds the national average. In response, Dr. Barbour, who leads the Norton Children’s Brain & Spinal Tumor program, helps lead new research…
After improving pediatric cancer survival from nearly nil in the 1950s to more than 85% today, health care providers face new challenges, especially long-term cognitive deficits associated with chemotherapy. In addition to attacking cancer cells, chemotherapy also can affect healthy cells, including those in the central nervous system. This can lead to a range of…
Pediatric oncology’s remarkable strides improving survival for children with cancer also has brought a new set of long-term health implications.
Kentucky leads the nation in cases of lung cancer. Cancer patients in our region also experience barriers to care and racial disparities in care. Cancer incidence in Kentucky is very high compared with other states, but lung cancer is far and away the most prevalent here. We have a 55% higher lung cancer rate than…
Monica H. Vetter, M.D., board-certified gynecologic oncologist at Norton Cancer Institute in Louisville, brings not only expertise in treating all types of gynecologic malignancies through a variety of techniques, including surgery and chemotherapy, but a deeply rooted passion as well. Native Kentuckian passionate about serving women in her home state As a Louisville native, Dr….
Clinical research, including clinical trials, is a crucial component to advancing the discovery of cancer therapeutics. Norton Cancer Institute contributes to this advancement through participation in numerous clinical trials every year. 4 phases of clinical trial There are four phases in a clinical trial, each with a different purpose. This helps researchers answer different questions…
The patient A 55-year-old woman developed increasing difficulties with constipation and abdominal discomfort over the course of several weeks. She then developed nausea with vomiting. She was found to have an obstructing colon cancer with multiple metastases to the liver and lung. After resection of her primary tumor, she required chemotherapy to treat her metastatic…
A painless lump on the side of the neck can have many causes, including benign conditions, infections or more serious diseases. Most commonly, swollen lymph nodes are the result of infection. Less commonly, it can be cancer. “Benign causes of a painless mass or neck swelling can include thyroid nodules, swelling of a saliva gland…
Norton Children’s has named a new physician to lead its cancer institute. Michael J. Ferguson, M.D., will serve as chief of Norton Children’s Cancer Institute and division chief of the University of Louisville School of Medicine Department of Pediatrics Division of Hematology, Oncology and Stem Cell Transplantation. In these roles, Dr. Ferguson will lead Norton…
Norton Cancer Institute is enrolling metastatic lung cancer patients in a Phase 3 clinical trial to test a promising new anti-CLTA-4 antibody, gotistobart (ONC-392). The study will test whether gotistobart is more effective than the chemotherapy agent docetaxel in prolonging life in patients with metastatic, non-small cell lung cancer whose disease progressed on anti-PD-1/PD-L1 antibody…